Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | CDX-585 |
Synonyms | |
Therapy Description |
CDX-585 is a bispecific antibody that targets PD-1 and ILT4, potentially resulting in enhanced antitumor immune response (Cancer Res (2023) 83 (7_Supplement): 2963). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CDX-585 | CDX 585|CDX585 | PD-L1/PD-1 antibody 117 | CDX-585 is a bispecific antibody that targets PD-1 and ILT4, potentially resulting in enhanced antitumor immune response (Cancer Res (2023) 83 (7_Supplement): 2963). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05788484 | Phase I | CDX-585 | A Study of CDX-585 in Patients With Advanced Malignancies | Recruiting | USA | 0 |